Volume 24, Number 1—January 2018
Research
Increased Severity and Spread of Mycobacterium ulcerans, Southeastern Australia
Alex Y.C. Tai
, Eugene Athan, N. Deborah Friedman, Andrew Hughes, Aaron Walton, and Daniel P. O’Brien
, Eugene Athan, N. Deborah Friedman, Andrew Hughes, Aaron Walton, and Daniel P. O’Brien
Table 2
Logistic regression analysis of adjusted and unadjusted associations between patient characteristics and severe Mycobacterium ulcerans disease, Barwon Health Cohort, Geelong, Victoria, Australia, January 1998–May 2017*
| Characteristic | Nonsevere disease, no. (%) | Severe disease, no. (%) | Crude odds ratio (95% CI) | p value | Adjusted odds ratio (95% CI) | p value |
|---|---|---|---|---|---|---|
| Age, y | ||||||
| ≤15 | 31 (77.5) | 9 (22.5) | 1.62 (0.71–3.71) | 0. 004 | 1.73 (0.73–4.12) | 0.006 |
| 16–64 | 184 (84.8) | 33 (15.2) | 1 | 1 | ||
| ≥65 |
120 (71.0) |
49 (29.0) |
2.28 (1.38–3.75) |
2.34 (1.38–3.98) |
||
| Sex | ||||||
| F | 156 (79.6) | 40 (20.4) | 1 | 0.66 | 1 | 0.51 |
| M |
179 (77.8) |
51 (22.2) |
1.11 (0.70–1.77 |
1.18 (0.72–1.94) |
||
| Location | ||||||
| Mornington Peninsula | 72 (70.6) | 30 (29.4) | 1 | 0.03 | 1 | 0.24 |
| Bellarine Peninsula |
263 (81.2) |
61 (18.8) |
0.56 (0.33–0.93) |
0.71 (0.40–1.26) |
||
| Lesion over a joint | ||||||
| No | 228 (84.4) | 42 (15.6) | 1 | <0.001 | 1 | <0.001 |
| Yes |
107 (68.6) |
49 (31.4) |
2.67 (1.64–4.36) |
2.71 (1.65–4.43) |
||
| Time period | ||||||
| 1998–2004 | 29 (85.3) | 5 (14.7) | 1 | 0.01 | 1 | 0.03 |
| 2005–2010 | 85 (87.6) | 12 (12.4) | 0.82 (0.27–2.52) | 0.88 (0.28–2.80) | ||
| 2011–2017 |
221 (74.9) |
74 (25.1) |
1.94 (0.73–5.20) |
2.11 (0.74–5.99) |
||
| Duration of symptoms before diagnosis, d | ||||||
| ≤75 | 241 (77.7) | 69 (22.3) | 1 | 0.76 | NA | NA |
| >75 | 81 (81.0) | 19 (19.0) | 0.82 (0.46–1.44) | |||
| Missing |
13 (81.3) |
3(18.8) |
0.81 (0.22–2.91) |
|||
| Diabetes mellitus | ||||||
| No | 312 (79.8) | 79 (20.2) | 1 | 0.06 | 1 | 0.14 |
| Yes |
23 (65.7) |
12 (34.3) |
2.06 (0.98–4.32) |
1.86 (0.82–4.23) |
||
| Immune suppression | ||||||
| No | 310 (79.3) | 81 (20.7) | 1 | 0.31 | NA | NA |
| Yes | 25 (71.4) | 10 (28.6) | 1.50 (0.69–3.27) | |||
*Adjusted for age, sex, location, position of lesion over a joint, time period, and diabetes mellitus. NA, not applicable.
Page created: December 19, 2017
Page updated: December 19, 2017
Page reviewed: December 19, 2017
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.